{"id":1068568,"date":"2024-08-03T02:35:44","date_gmt":"2024-08-03T06:35:44","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/fda-grants-orphan-drug-designation-to-cellectis-clls52-alemtuzumab-for-all-treatment\/"},"modified":"2024-08-18T11:48:57","modified_gmt":"2024-08-18T15:48:57","slug":"fda-grants-orphan-drug-designation-to-cellectis-clls52-alemtuzumab-for-all-treatment","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/fda-grants-orphan-drug-designation-to-cellectis-clls52-alemtuzumab-for-all-treatment.php","title":{"rendered":"FDA Grants Orphan Drug Designation to Cellectis\u2019 CLLS52 (alemtuzumab)\u00a0For ALL Treatment"},"content":{"rendered":"<p><![CDATA[NEW YORK, Aug.  01, 2024  (GLOBE NEWSWIRE) -- Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS - NASDAQ:\u00a0 CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Cellectis\u2019 CLLS52 (alemtuzumab), an Investigational Medicinal Product (IMP) used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed\/refractory B-cell acute lymphoblastic leukemia (ALL).]]><\/p>\n<p>Follow this link:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/08\/01\/2923264\/0\/en\/FDA-Grants-Orphan-Drug-Designation-to-Cellectis-CLLS52-alemtuzumab-For-ALL-Treatment.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"FDA Grants Orphan Drug Designation to Cellectis\u2019 CLLS52 (alemtuzumab)\u00a0For ALL Treatment\">FDA Grants Orphan Drug Designation to Cellectis\u2019 CLLS52 (alemtuzumab)\u00a0For ALL Treatment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Follow this link: FDA Grants Orphan Drug Designation to Cellectis\u2019 CLLS52 (alemtuzumab)\u00a0For ALL Treatment <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/fda-grants-orphan-drug-designation-to-cellectis-clls52-alemtuzumab-for-all-treatment.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068568","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068568"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068568"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}